<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2021-4640</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-4640</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Связь сниженной скорости клубочковой фильтрации с нарушениями ренальной гемодинамики и биомаркерами воспаления у пациентов с медикаментозно контролируемой артериальной гипертонией высокого сердечно-сосудистого риска</article-title><trans-title-group xml:lang="en"><trans-title>Association of decreased glomerular filtration rate with renal hemodynamic disorders and inflammatory biomarkers in patients with medically-controlled hypertension of high cardiovascular risk</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6679-1269</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кошельская</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koshelskaya</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кошельская Ольга Анатольевна — доктор медицинских наук, профессор, ведущий научный сотрудник, отделение атеросклероза и хронической ишемической болезни сердца</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">koshel@live.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0106-6813</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Журавлева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhuravleva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Журавлева Ольга Александровна — кандидат медицинских наук, научный сотрудник отделения атеросклероза и хронической ишемической болезни сердца</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">olgazh.cardio@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4537-0008</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кологривова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kologrivova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кологривова Ирина Вячеславовна — кандидат медицинских наук, научный сотрудник, отделение функциональной и лабораторной диагностики</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">ikologrivova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8890-9814</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марголис</surname><given-names>Н. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Margolis</surname><given-names>N. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марголис Наталья Юрьевна — кандидат те6хнических наук, специалист по биомедицинской статистике отдела координации научной и образовательной деятельности</p><p>Томск</p></bio><bio xml:lang="en"><p>Tomsk</p></bio><email xlink:type="simple">mny@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Tomsk National Research Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>25</day><month>08</month><year>2021</year></pub-date><volume>26</volume><issue>9</issue><fpage>4640</fpage><lpage>4640</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кошельская О.А., Журавлева О.А., Кологривова И.В., Марголис Н.Ю., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Кошельская О.А., Журавлева О.А., Кологривова И.В., Марголис Н.Ю.</copyright-holder><copyright-holder xml:lang="en">Koshelskaya O.A., Zhuravleva O.A., Kologrivova I.V., Margolis N.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/4640">https://russjcardiol.elpub.ru/jour/article/view/4640</self-uri><abstract><sec><title>Цель</title><p>Цель. У пациентов с медикаментозно контролируемой артериальной гипертонией (АГ) (&lt;140/90 мм рт.ст.) определить частоту выявления маркеров хронической болезни почек (ХБП), проанализировать потенциальные связи сниженной скорости клубочковой фильтрации (СКФ) &lt;60 мл/мин/1,73 м2 с клиническими данными и характером терапии; установить значимые детерминанты снижения СКФ у этой категории пациентов.</p></sec><sec><title>Материал и  методы</title><p>Материал и  методы. В  исследование включены 70 пациентов с АГ и уровнем офисного артериального давления (АД) &lt;140/90  мм рт.ст. в  возрасте 64 (57; 68) года, 48,6% мужчин, из них 40 пациентов обследованы в  рамках Российской многоцентровой программы ХРОНОГРАФ. Офисное АД в  группе составило 130 (120; 140)/80 (72; 82) мм рт.ст. Рассчитывали СКФ, определяли альбуминурию, проводили суточное мониторирование АД, ультразвуковое допплеровское исследование почечного кровотока с  расчетом резистивных индексов (РИ). Определяли содержание в  сыворотке крови высокочувствительного С-реактивного белка (вчСРБ), интерлейкинов (ИЛ) 1β, 6, 10 и показателей липидтранспортной функции крови.</p></sec><sec><title>Заключение</title><p>Заключение. Среди пациентов c медикаментозно контролируемой АГ высокого сердечно-сосудистого риска выявлена значительная частота маркеров ХБП (31,4%). В сравнении с пациентами с сохранной функцией почек, при наличии маркеров ХБП имеют место более высокие уровни офисного систолического АД, ночного пульсового АД, содержания в крови вчСРБ и значений интраренальной резистивности. Установлены ассоциации между величиной СКФ и уровнями вчСРБ, ИЛ-1β и ИЛ-10, что подтверждает патологическую роль воспалительных биомаркеров в формировании почечной дисфункции при АГ высокого сердечно-сосудистого риска. Возраст, повышенные уровни вчСРБ крови и значений интраренальной резистивности являются независимыми детерминантами снижения СКФ у пациентов с медикаментозной контролируемой АГ высокого и очень высокого сердечно-сосудистого риска. Полученные данные обосновывают необходимость раннего назначения у этой категории пациентов комбинированной антигипертензивной терапии с дополнительными нефрои вазопротективными свойствами, а также с доказанной способностью ограничивать процессы хронического субклинического воспаления.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To assess markers of chronic kidney disease (CKD) in patients with medically-controlled hypertension (HTN) (&lt;140/90 mm Hg), as well as to analyze potential association of decreased glomerular filtration rate (GFR) &lt;60 ml/min/1,73 m2 with clinical data and therapy; to establish significant determinants of GFR decrease in this category of patients.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 70 patients with HTN and office blood pressure (BP) &lt;140/90 mm Hg aged 64 (57; 68) years (men, 48,6%), of whom 40 patients were examined within the Russian multicenter CHRONOGRAPH program. Office BP was 130 (120; 140)/80 (72; 82) mm Hg. GFR and albuminuria were assessed. Twenty-four-hour BP monitoring and Doppler ultrasound of renal blood flow with estimation of resistance indices (RI) were performed. The content of highsensitivity C-reactive protein (hsCRP), interleukins (IL) 1β, 6, 10 and lipid transport function parameters was determined.</p></sec><sec><title>Results</title><p>Results. CKD markers were detected in 31,4% of patients (in 27,1% — a decrease in GFR &lt;60 ml/min/1,73 m2; in 12,9% — pathological albuminuria). Patients with CKD markers were older, had higher office systolic BP and nocturnal pulse pressure, higher blood hsCRP and RI levels throughout the renal flow, and lower high-density lipoprotein cholesterol levels. In the presence of CKD markers, calcium channel blockers, aldosterone receptor antagonists and statins were used more often. The results of correlation analysis were used to determine the determinants of GFR decline. In the general group, GFR values had inverse correlations with age (Rs=-0,58, p&lt;0,0001), segmental intrarenal artery RI (Rs= -0,4232, p=0,0005), blood hsCRP (Rs=-0,3998, p=0,0007), IL-1β (Rs=-0,3139, p=0,0086), office BP and some 24-hour BP parameters. In the presence of CKD markers, a direct association of GFR and IL-10 was determined (Rs=0,4293, p=0,046). In the absence of such markers, GFR had an inverse correlation with IL-1β content (Rs=-0,3110, p=0,0333). A multiple linear regression model included following independent determinants of GFR: age, blood hsCRP and RI in the segmental intrarenal arteries.</p></sec><sec><title>Conclusion</title><p>Conclusion. Among patients with medically-controlled HTN of high cardiovascular risk, a high prevalence of CKD markers was revealed (31,4%). Compared with patients with preserved renal function, in the presence of CKD markers, there were higher levels of office systolic BP, nocturnal pulse pressure, blood hsCRP, and intrarenal artery RI. Associations were established between GFR and the levels of hsCRP, IL-1β and IL-10, which confirms the pathological role of inflammatory biomarkers in developing renal dysfunction in high-risk HTN. Age, elevated blood hsCRP levels, and intrarenal artery RI are independent determinants of decreased GFR in patients with medically-controlled HTN of high and very high cardiovascular risk. The data obtained shows the need for early prescription of combination antihypertensive therapy with nephro- and vasoprotective effects in this category of patients, as well as with an ability to depress the chronic subclinical inflammation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>артериальная гипертония</kwd><kwd>биомаркеры воспаления</kwd><kwd>внутрипочечное сосудистое сопротивление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic kidney disease</kwd><kwd>hypertension</kwd><kwd>inflammatory biomarkers</kwd><kwd>intrarenal vascular resistance</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.</mixed-citation><mixed-citation xml:lang="en">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai WC, Wu HY, Peng YS, et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore). 2016;95(11):e3013. doi:10.1097/MD.0000000000003013.</mixed-citation><mixed-citation xml:lang="en">Tsai WC, Wu HY, Peng YS, et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore). 2016;95(11):e3013. doi:10.1097/MD.0000000000003013.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Major RW, Cheng MRI, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018;13(3):e0192895. doi:10.1371/journal.pone.0192895.</mixed-citation><mixed-citation xml:lang="en">Major RW, Cheng MRI, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018;13(3):e0192895. doi:10.1371/journal.pone.0192895.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Halimi J.-M. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes&amp;Metabolism. 2012;38:291-7. doi:10.1016/j.diabet.2012.04.001.</mixed-citation><mixed-citation xml:lang="en">Halimi J.-M. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes&amp;Metabolism. 2012;38:291-7. doi:10.1016/j.diabet.2012.04.001.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ощепкова Е.В., Долгушева Ю.А., Жернакова Ю.В. и др. Распространенность нарушения функции почек при артериальной гипертонии (по данным эпидемиологического исследования ЭССЕ-РФ). Системные гипертензии. 2015;12(3):19-24. doi:10.26442/2075-082X_12.3.19-24.</mixed-citation><mixed-citation xml:lang="en">Oschepkova EV, Dolgusheva YA, Zhernakova YV, et al. The prevalence of renal dysfunction in arterial hypertension (according to the epidemiological study of ESSE-RF). Systemic hypertension. 2015;12(3):19-24. (In Russ.) doi:10.26442/2075-082X_12.3.19-24.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж. Д., Виллевальде С.В., Боровкова Н.Ю. и др. от имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017;57(10):39-44. doi:10.18087/cardio.2017.10.10041.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD, Villevalde SV, Borovkova NY. Prevalence of Markers of Chronic Kidney Disease in Patients With Arterial Hypertension: Results of Epidemiological Study CHRONOGRAF. Cardiology. 2017;57(10):39-44. (In Russ.) doi:10.18087/cardio.2017.10.10041.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Doi Y, Iwashima Y, Yoshihara F, et al. Renal resistive index and cardiovascular and renal outcomes in essential hypertension. Hypertension. 2012;60:770-7. doi:10.1161/hypertensionaha.112.196717.</mixed-citation><mixed-citation xml:lang="en">Doi Y, Iwashima Y, Yoshihara F, et al. Renal resistive index and cardiovascular and renal outcomes in essential hypertension. Hypertension. 2012;60:770-7. doi:10.1161/hypertensionaha.112.196717.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Calabia J, Torguet P, Garcia I, et al. The Relationship Between Renal Resistive Index, Arterial Stiffness, and Atherosclerotic Burden: The Link Between Macrocirculation and Microcirculation. The Journal of Clinical Hypertension. 2014;16(3):186-91. doi:10.1111/jch.12248.</mixed-citation><mixed-citation xml:lang="en">Calabia J, Torguet P, Garcia I, et al. The Relationship Between Renal Resistive Index, Arterial Stiffness, and Atherosclerotic Burden: The Link Between Macrocirculation and Microcirculation. The Journal of Clinical Hypertension. 2014;16(3):186-91. doi:10.1111/jch.12248.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kawai T, Kamide K, Onishi M, et al. Usefulness of the resistive index in renal Doppler ultrasonography as an indicator of vascular damage in patients with risks of atherosclerosis. Nephrol Dial Transplant. 2011;26:3256-62. doi:10.1093/ndt/gfr054.</mixed-citation><mixed-citation xml:lang="en">Kawai T, Kamide K, Onishi M, et al. Usefulness of the resistive index in renal Doppler ultrasonography as an indicator of vascular damage in patients with risks of atherosclerosis. Nephrol Dial Transplant. 2011;26:3256-62. doi:10.1093/ndt/gfr054.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Amdur RL, Feldman HI, Gupta J, et al. and the CRIC Study Investigators. Inflammation and Progression of CKD: The CRIC Study. CJASN. 2016;11(9):1546-56. doi:10.2215/CJN.13121215.</mixed-citation><mixed-citation xml:lang="en">Amdur RL, Feldman HI, Gupta J, et al. and the CRIC Study Investigators. Inflammation and Progression of CKD: The CRIC Study. CJASN. 2016;11(9):1546-56. doi:10.2215/CJN.13121215.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Garofalo C, Borrelli S, Pacilio M, et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. Am J Kidney Dis. 2016;67(1):89-97. doi:10.1053/j.ajkd.2015.08.027.</mixed-citation><mixed-citation xml:lang="en">Garofalo C, Borrelli S, Pacilio M, et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. Am J Kidney Dis. 2016;67(1):89-97. doi:10.1053/j.ajkd.2015.08.027.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dincer N, Dagel T, Afsar B, et al. The effect of chronic kidney disease on lipid metabolism. International Urology and Nephrology. 2018;51:265-77. doi:10.1007/s11255-018-2047-y.</mixed-citation><mixed-citation xml:lang="en">Dincer N, Dagel T, Afsar B, et al. The effect of chronic kidney disease on lipid metabolism. International Urology and Nephrology. 2018;51:265-77. doi:10.1007/s11255-018-2047-y.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sinuani I, Beberashvili I, Averbukh Z, et al. Role of IL-10 in the progression of kidney disease. World J Transplant. 2013;3(4):91-8. doi:10.5500/wjt.v3.i4.91.</mixed-citation><mixed-citation xml:lang="en">Sinuani I, Beberashvili I, Averbukh Z, et al. Role of IL-10 in the progression of kidney disease. World J Transplant. 2013;3(4):91-8. doi:10.5500/wjt.v3.i4.91.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jin Y, Liu R, Xie J, et al. Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model. Lab Invest. 2013;93:801-11. doi:10.1038/labinvest.2013.64.</mixed-citation><mixed-citation xml:lang="en">Jin Y, Liu R, Xie J, et al. Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model. Lab Invest. 2013;93:801-11. doi:10.1038/labinvest.2013.64.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Anders HJ. Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease. J Am Soc Nephrol. 2016;27(9):2564-75. doi:10.1681/ASN.2016020177.</mixed-citation><mixed-citation xml:lang="en">Anders HJ. Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease. J Am Soc Nephrol. 2016;27(9):2564-75. doi:10.1681/ASN.2016020177.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tinti F, Lai S, Noce A, et al. Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment. Life (Basel). 2021;11(5):419. doi:10.3390/life11050419.</mixed-citation><mixed-citation xml:lang="en">Tinti F, Lai S, Noce A, et al. Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment. Life (Basel). 2021;11(5):419. doi:10.3390/life11050419.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2018;71(21):2405-14. doi:10.1016/j.jacc.2018.03.490.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2018;71(21):2405-14. doi:10.1016/j.jacc.2018.03.490.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Фальковская А.Ю., Мордовин В.Ф., Пекарский С.Е. и др. Система матриксных металлопротеиназ у больных резистентной артериальной гипертензией, ассоциированной с сахарным диабетом 2го типа: связь с состоянием почечного кровотока и функцией почек. Артериальная гипертензия. 2019;25(1):34-45. doi:10.18705/1607-419X-2019-25-1-34-45.</mixed-citation><mixed-citation xml:lang="en">Falkovskaya AY, MordovinVF, Pekarskiy SE, et al. Matrix metalloproteinases in patients with resistant hypertension and type 2 diabetes mellitus: relation with renal blood flow and kidney function. Arterial Hypertension. 2019;25(1):34-45. (In Russ.) doi:10.18705/1607-419X-2019-25-1-34-45.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. JHypertens. 2018;36(10):1953- 2041.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. JHypertens. 2018;36(10):1953- 2041.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Chang AR, Lóser M, Malhotra R, Appel LJ. Blood Pressure Goals in Patients With CKD: A Review of Evidence and Guidelines. Clin J Am Soc Nephrol. 2019;14(1):161-9. doi:10.2215/CJN.07440618.</mixed-citation><mixed-citation xml:lang="en">Chang AR, Lóser M, Malhotra R, Appel LJ. Blood Pressure Goals in Patients With CKD: A Review of Evidence and Guidelines. Clin J Am Soc Nephrol. 2019;14(1):161-9. doi:10.2215/CJN.07440618.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tsioufis C, Andrikou I, Thomopoulos C, et al. Comparative prognostic role of nighttime blood pressure and nondipping profile on renal outcomes. Am J Nephrol. 2011;33:277-88. doi:10.1159/000324697.</mixed-citation><mixed-citation xml:lang="en">Tsioufis C, Andrikou I, Thomopoulos C, et al. Comparative prognostic role of nighttime blood pressure and nondipping profile on renal outcomes. Am J Nephrol. 2011;33:277-88. doi:10.1159/000324697.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Журавлева О.А., Винницкая И.В., Кошельская О.А. Внутрипочечное сосудистое сопротивление у больных артериальной гипертонией и сахарным диабетом: связь с уровнем артериального давления и величиной скорости клубочковой фильтрации. Сибирский журнал клинической и экспериментальной медицины. 2016;31(1):17-21. doi:10.29001/2073-8552-2016-31-1-17-21.</mixed-citation><mixed-citation xml:lang="en">Zhuravleva OA, Vinnitskaya IV, Koshelskaya OA. Intrarenal vascular resistance in patients with arterial hypertension and diabetes mellitus: relation to the level of arterial blood pressure and value of glomerular filtration rate. The Siberian Journal of Clinical and Experimental Medicine. 2016;31(1):17-21. (In Russ.) doi:10.29001/2073-8552-2016-31-1-17-21.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881-900. doi:10.1016/s1357-2725(02)00271-6.</mixed-citation><mixed-citation xml:lang="en">Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881-900. doi:10.1016/s1357-2725(02)00271-6.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Ortega M, Esteban V, Rupérez M, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens. 2006;15(2):159-66. doi:10.1097/01.mnh.0000203190.34643.d4.</mixed-citation><mixed-citation xml:lang="en">Ruiz-Ortega M, Esteban V, Rupérez M, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens. 2006;15(2):159-66. doi:10.1097/01.mnh.0000203190.34643.d4.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J. 2009;157(6 Suppl):S7-S16. doi:10.1016/j.ahj.2009.04.008.</mixed-citation><mixed-citation xml:lang="en">Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J. 2009;157(6 Suppl):S7-S16. doi:10.1016/j.ahj.2009.04.008.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: New roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247-57. doi:10.1002/emmm.201000080.</mixed-citation><mixed-citation xml:lang="en">Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: New roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247-57. doi:10.1002/emmm.201000080.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67:799-812. doi:10.1111/j.1523-1755.2005.00145.x</mixed-citation><mixed-citation xml:lang="en">Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67:799-812. doi:10.1111/j.1523-1755.2005.00145.x</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrari R, Pasanisi G, Notarstefano P, et al. Specific Properties and Effect of Perindopril in Controlling the Renin-Angiotensin System American Journal of Hypertension. 2005;18(S5):142S-154S. doi:10.1016/j.amjhyper.2005.05.037.</mixed-citation><mixed-citation xml:lang="en">Ferrari R, Pasanisi G, Notarstefano P, et al. Specific Properties and Effect of Perindopril in Controlling the Renin-Angiotensin System American Journal of Hypertension. 2005;18(S5):142S-154S. doi:10.1016/j.amjhyper.2005.05.037.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Зверева Т.Н., Чернявская Е.Ю., Барбараш О. Л. Влияние периндоприла на процессы субклинического воспаления у больных артериальной гипертензией и сахарным диабетом 2-го типа. Кардиология. 2013;53(4):19-24.</mixed-citation><mixed-citation xml:lang="en">Zvereva TN, Cherniavskaia EI, Barbarash OL. Effect of perindopril on the processes of subclinical inflammation in patients with arterial hypertension and type 2 diabetes mellitus. Cardiology. 2013;53(4):19-24. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Ma F, Lin F, Chen C, et al. Indapamide Lowers Blood Pressure by Increasing Production of Epoxyeicosatrienoic Acids in the Kidney. Mol Pharmacol. 2013;84(2):286-95. doi:10.1124/mol.113.085878.</mixed-citation><mixed-citation xml:lang="en">Ma F, Lin F, Chen C, et al. Indapamide Lowers Blood Pressure by Increasing Production of Epoxyeicosatrienoic Acids in the Kidney. Mol Pharmacol. 2013;84(2):286-95. doi:10.1124/mol.113.085878.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S, Li J, Zhou X, et al. Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan. J Hum Hypertens. 2017;31:848-54. doi:10.1038/jhh.2017.51.</mixed-citation><mixed-citation xml:lang="en">Wang S, Li J, Zhou X, et al. Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan. J Hum Hypertens. 2017;31:848-54. doi:10.1038/jhh.2017.51.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Аксенова А.В., Елфимова Е.М., Литвин А.Ю., Чазова И.Е. Изучение возможностей хронотерапии при назначении фиксированной комбинации перидоприла 10 мг и индапамида 2,5 мг (Нолипрел А Би-форте) у пациентов с недостаточной степенью снижения артериального давления в ночное время. Системные гипертензии.2016;13(2):37-45. doi:10.26442/SG29137.</mixed-citation><mixed-citation xml:lang="en">Aksenova AV, Elfimova EM, Litvin AY, Chazova IE. Chronotherapy’s opportunities of a fixed combination of perindopril 10mg/indapamide 2,5mg in patients with a lack of night reduction in blood pressure. Systemic Hypertension. 2016;13(2):37-45. (In Russ.) doi:10.26442/SG29137.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003;41:1063-71. doi:10.1161/01.HYP.0000064943.51878.58.</mixed-citation><mixed-citation xml:lang="en">Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003;41:1063-71. doi:10.1161/01.HYP.0000064943.51878.58.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Struijker-Boudier HA. From Macrocirculation to Microcirculation: Benefits of Preterax. American J of Hypertension. 2007;20:15S-18S. doi:10.1016/j.amjhyper.2007.04.013.</mixed-citation><mixed-citation xml:lang="en">Struijker-Boudier HA. From Macrocirculation to Microcirculation: Benefits of Preterax. American J of Hypertension. 2007;20:15S-18S. doi:10.1016/j.amjhyper.2007.04.013.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Zannad F. Benefits of First-Line Combination of Perindopril and Indapamide in Clinical Practice for Patients With Hypertension and Diabetes. American J of Hypertension. 2007;20:9S-14S. doi:10.1016/j.amjhyper.2007.04.014.</mixed-citation><mixed-citation xml:lang="en">Zannad F. Benefits of First-Line Combination of Perindopril and Indapamide in Clinical Practice for Patients With Hypertension and Diabetes. American J of Hypertension. 2007;20:9S-14S. doi:10.1016/j.amjhyper.2007.04.014.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63(2):259-64. doi:10.1161/HYPERTENSIONAHA.113.02252.</mixed-citation><mixed-citation xml:lang="en">Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63(2):259-64. doi:10.1161/HYPERTENSIONAHA.113.02252.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Tóth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45. doi:10.1007/s40256-014-0067-2.</mixed-citation><mixed-citation xml:lang="en">Tóth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45. doi:10.1007/s40256-014-0067-2.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж.Д., Троицкая Е.А., Толкачева В.В. Комбинированная терапия артериальной гипертонии с использованием трехкомпонентной фиксированной комбинации амлодипина, индапамида и периндоприла аргинина в клинической практике: организация и основные результаты программы ДОКАЗАТЕЛЬСТВО. Кардиология. 2018;58(9):21-30. doi:10.18087/cardio.2018.9.10170.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZD, Troitskaya EA, Tolkacheva VV. Combined Therapy of Arterial Hypertension With a Triple Fixed-Dose Combination of Amlodipine/Indapamide/Perindopril Arginine in Real Clinical Practice: the Organization and the Main Results of the DOKAZATEL’STVO (Proof) Study. Cardiology. 2018;58(9):21-30. (In Russ.) doi:10.18087/cardio.2018.9.10170.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine and fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(12):1042-9. doi:10.1016/s0895-7061(02)03017-0.</mixed-citation><mixed-citation xml:lang="en">Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine and fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(12):1042-9. doi:10.1016/s0895-7061(02)03017-0.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazeprilamlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47(5):636-42. doi:10.1097/01.fjc.0000211750.01326.b3.</mixed-citation><mixed-citation xml:lang="en">Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazeprilamlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47(5):636-42. doi:10.1097/01.fjc.0000211750.01326.b3.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Искендеров Б.Г., Будаговская З.М., Сисина О.Н. Влияние фиксированной комбинации периндоприла и амлодипина на показатели внутрипочечной гемодинамики и функциональное состояние почек у больных эссенциальной артериальной гипертонией. Терапевтический архив. 2013;85(5):78-83.</mixed-citation><mixed-citation xml:lang="en">Iskenderov BG, Budagovskaia ZM, Sisina ON. Effect of a fixed-dose perindopril and amlodipine combination on intrarenal hemodynamic and kidney functional parameters in patients with essential hypertension. Terapevticheskii arkhiv. 2013;85(5):78-83. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Кошельская О.А., Журавлева О.А., Карпов Р.С. Влияние разных схем антигипертензивной терапии с достижением целевых значений артериального давления на состояние функции почек и внутрипочечное сосудистое сопротивление у больных сахарным диабетом типа 2. Системные гипертензии. 2013;10(3):60-5. doi:10.20996/1819-6446-2012-8-3-433-440.</mixed-citation><mixed-citation xml:lang="en">Koshelskaya OA, Zhuravleva OA, Karpov RS. Effect of target blood pressure achieved during combined antihypertensive therapy on intrarenal vascular resistance in hypertensive diabetic patients. Systemic Hypertension Journal. 2013;10(3):60-5. (In Russ.) doi:10.20996/1819-6446-2012-8-3-433-440.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Osende JI, Ruiz-Ortega M, Blanco-Colio LM, Egido J. Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study. Nephrol Dial Transplant. 2004;19:528-31. doi:10.1093/ndt/gfg538.</mixed-citation><mixed-citation xml:lang="en">Osende JI, Ruiz-Ortega M, Blanco-Colio LM, Egido J. Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study. Nephrol Dial Transplant. 2004;19:528-31. doi:10.1093/ndt/gfg538.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
